Abcam, ab249264, Anti-K23 antibody [EPR10943] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal K23 antibody. Carrier free. Suitable for IHC-P, WB, Flow Cyt (Intra) and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR10943,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, Flow Cyt (Intra), WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249264 is the carrier-free version of
ab156569
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
K23 also known as SUMO-3 is a small ubiquitin-like modifier protein with a mass of approximately 11 kDa. It shares structural similarities with ubiquitin allowing it to form covalent attachments to target proteins. K23 is ubiquitously expressed in the cell primarily in the nucleus but also found in the cytoplasm. The protein is involved in various cellular processes through reversible post-translational modifications.
Biological function summary
The attachment of K23 to target proteins influences their stability localization and interactions. It often modifies transcription factors and other nuclear proteins altering gene expression patterns. K23 is part of the SUMO modification complex that includes enzymes like E1-activating E2-conjugating and E3-ligase proteins. This post-translational modification process affects several cellular pathways and maintains cellular homeostasis.
Pathways
SUMOylation influences important pathways like DNA damage response and cell cycle regulation. K23 plays a significant role in DNA repair mechanisms and mitotic progression by modifying proteins such as p53 and RanGAP1. These modifications are vital for the proper execution of cellular tasks and communication with related proteins that share these pathways including SUMO-1 and SUMO-2 which often compensate for each other's functions.
Dysfunction in K23 modification contributes to conditions like cancer and neurodegenerative diseases. In cancers abnormal SUMOylation mediated by K23 impacts cellular proliferation and survival pathways often involving dysregulation of proteins like p53. Neurodegenerative diseases also show altered levels of SUMOylated proteins implicating K23 in modifications that affect neuronal function and integrity. Researchers focus on these diseases to explore therapeutic potential targeting the SUMOylation pathway.